Details for New Drug Application (NDA): 218661
✉ Email this page to a colleague
NDA 218661 describes SELENIOUS ACID, which is a drug marketed by Am Regent, Aspiro, Cipla, Fresenius Kabi Usa, Gland, and Sun Pharm, and is included in six NDAs. It is available from three suppliers. There are two patents protecting this drug. Additional details are available on the SELENIOUS ACID profile page.
The generic ingredient in SELENIOUS ACID is selenious acid. Three suppliers are listed for this compound. Additional details are available on the selenious acid profile page.
The generic ingredient in SELENIOUS ACID is selenious acid. Three suppliers are listed for this compound. Additional details are available on the selenious acid profile page.
Summary for 218661
| Tradename: | SELENIOUS ACID |
| Applicant: | Cipla |
| Ingredient: | selenious acid |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML) | ||||
| Approval Date: | Jul 21, 2025 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | ||||
| Approval Date: | Jul 21, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
